Environmental hazard testing of nanobiomaterials

M. J.B. Amorim; M. L. Fernández-Cruz; K. Hund-Rinke; J. J. Scott-Fordsmand

doi:10.1186/s12302-020-00369-8

Environmental hazard testing of nanobiomaterials

M. J.B. Amorim^*
, M. L. Fernández-Cruz
, K. Hund-Rinke
, J. J. Scott-Fordsmand

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

18 Citationer (Scopus)

37 Downloads (Pure)

Abstract

The European Medicines Agency (EMA) regards the potential risks of human medicinal products to the environment and their impacts are assessed, as well as management to limit this impact. Hazard assessment of novel materials, which differ from conventional chemicals, e.g. nanobiomaterials, poses testing challenges and represents a work-in-progress with much focus on the optimization of required methodologies. For this work-in-progress, we here highlight where changes/updates are required in relation to the main elements for international testing based on OECD guidelines, supported by knowledge from the nanotoxicity area. The outline describes two major sections, nanobiomaterials and environmental hazards, including its challenges and learned lessons, with recommendations for implementation in OECD guidelines. Finally, the way forward via a testing strategy is described.[Figure not available: see fulltext.].

Originalsprog	Engelsk
Artikelnummer	101
Tidsskrift	Environmental Sciences Europe
Vol/bind	32
Nummer	1
Antal sider	13
ISSN	2190-4707
DOI	https://doi.org/10.1186/s12302-020-00369-8
Status	Udgivet - 2020

Adgang til dokumentet

10.1186/s12302-020-00369-8

s12302-020-00369-8Forlagets udgivne version, 1,15 MBLicens: CC BY

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Andre filer og links

https://www.scopus.com/pages/publications/85088303273

Citationsformater

@article{83ca4eac22a54dfab601623f9d0b7501,

title = "Environmental hazard testing of nanobiomaterials",

abstract = "The European Medicines Agency (EMA) regards the potential risks of human medicinal products to the environment and their impacts are assessed, as well as management to limit this impact. Hazard assessment of novel materials, which differ from conventional chemicals, e.g. nanobiomaterials, poses testing challenges and represents a work-in-progress with much focus on the optimization of required methodologies. For this work-in-progress, we here highlight where changes/updates are required in relation to the main elements for international testing based on OECD guidelines, supported by knowledge from the nanotoxicity area. The outline describes two major sections, nanobiomaterials and environmental hazards, including its challenges and learned lessons, with recommendations for implementation in OECD guidelines. Finally, the way forward via a testing strategy is described.[Figure not available: see fulltext.].",

keywords = "Advanced therapy medicinal products, Medical devices, Nanobiomaterials, Nanomedicine, OECD standardization",

author = "Amorim, \{M. J.B.\} and Fern{\'a}ndez-Cruz, \{M. L.\} and K. Hund-Rinke and Scott-Fordsmand, \{J. J.\}",

year = "2020",

doi = "10.1186/s12302-020-00369-8",

language = "English",

volume = "32",

journal = "Environmental Sciences Europe",

issn = "2190-4707",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Environmental hazard testing of nanobiomaterials

AU - Amorim, M. J.B.

AU - Fernández-Cruz, M. L.

AU - Hund-Rinke, K.

AU - Scott-Fordsmand, J. J.

PY - 2020

Y1 - 2020

N2 - The European Medicines Agency (EMA) regards the potential risks of human medicinal products to the environment and their impacts are assessed, as well as management to limit this impact. Hazard assessment of novel materials, which differ from conventional chemicals, e.g. nanobiomaterials, poses testing challenges and represents a work-in-progress with much focus on the optimization of required methodologies. For this work-in-progress, we here highlight where changes/updates are required in relation to the main elements for international testing based on OECD guidelines, supported by knowledge from the nanotoxicity area. The outline describes two major sections, nanobiomaterials and environmental hazards, including its challenges and learned lessons, with recommendations for implementation in OECD guidelines. Finally, the way forward via a testing strategy is described.[Figure not available: see fulltext.].

AB - The European Medicines Agency (EMA) regards the potential risks of human medicinal products to the environment and their impacts are assessed, as well as management to limit this impact. Hazard assessment of novel materials, which differ from conventional chemicals, e.g. nanobiomaterials, poses testing challenges and represents a work-in-progress with much focus on the optimization of required methodologies. For this work-in-progress, we here highlight where changes/updates are required in relation to the main elements for international testing based on OECD guidelines, supported by knowledge from the nanotoxicity area. The outline describes two major sections, nanobiomaterials and environmental hazards, including its challenges and learned lessons, with recommendations for implementation in OECD guidelines. Finally, the way forward via a testing strategy is described.[Figure not available: see fulltext.].

KW - Advanced therapy medicinal products

KW - Medical devices

KW - Nanobiomaterials

KW - Nanomedicine

KW - OECD standardization

UR - https://www.scopus.com/pages/publications/85088303273

U2 - 10.1186/s12302-020-00369-8

DO - 10.1186/s12302-020-00369-8

M3 - Journal article

AN - SCOPUS:85088303273

SN - 2190-4707

VL - 32

JO - Environmental Sciences Europe

JF - Environmental Sciences Europe

IS - 1

M1 - 101

ER -

Environmental hazard testing of nanobiomaterials

Abstract

Adgang til dokumentet

Biblioteksadgang?

Andre filer og links

Fingeraftryk

Citationsformater